MA32878B1 - Virus syncytial respiratoire vivant attenue - Google Patents

Virus syncytial respiratoire vivant attenue

Info

Publication number
MA32878B1
MA32878B1 MA33913A MA33913A MA32878B1 MA 32878 B1 MA32878 B1 MA 32878B1 MA 33913 A MA33913 A MA 33913A MA 33913 A MA33913 A MA 33913A MA 32878 B1 MA32878 B1 MA 32878B1
Authority
MA
Morocco
Prior art keywords
vsr
respiratory syncytial
syncytial virus
virus attenuated
attenuated
Prior art date
Application number
MA33913A
Other languages
Arabic (ar)
English (en)
Inventor
Mary K Yagodich
Michael P Citron
Daniel J Distefano
David L Krah
Xiaoping Liang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA32878B1 publication Critical patent/MA32878B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18564—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un virus syncytial respiratoire (VSR) vivant atténué utile contre les infections par le VSR et/ou le développement de syndromes aigus associés au VSR. Ledit virus, atténué jusqu'à devenir non pathogène lorsqu'administré à un sujet, conserve néanmoins les propriétés antigènes et immunogènes du VSR de type sauvage.
MA33913A 2008-11-05 2011-06-03 Virus syncytial respiratoire vivant attenue MA32878B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19832708P 2008-11-05 2008-11-05
PCT/US2009/063024 WO2010053883A1 (fr) 2008-11-05 2009-11-03 Virus syncytial respiratoire vivant atténué

Publications (1)

Publication Number Publication Date
MA32878B1 true MA32878B1 (fr) 2011-12-01

Family

ID=41527812

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33913A MA32878B1 (fr) 2008-11-05 2011-06-03 Virus syncytial respiratoire vivant attenue

Country Status (19)

Country Link
US (1) US9011876B2 (fr)
EP (1) EP2346990B1 (fr)
JP (2) JP5016731B2 (fr)
KR (1) KR20110063863A (fr)
CN (1) CN102272295A (fr)
AU (1) AU2009311287C1 (fr)
BR (1) BRPI0921424A2 (fr)
CA (1) CA2742086A1 (fr)
CL (1) CL2011000999A1 (fr)
CO (1) CO6362047A2 (fr)
EC (1) ECSP11011033A (fr)
IL (1) IL212437A0 (fr)
MA (1) MA32878B1 (fr)
MX (1) MX2011004719A (fr)
PE (1) PE20110394A1 (fr)
RU (1) RU2011122615A (fr)
TN (1) TN2011000182A1 (fr)
WO (1) WO2010053883A1 (fr)
ZA (1) ZA201103259B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110063863A (ko) * 2008-11-05 2011-06-14 머크 샤프 앤드 돔 코포레이션 생 약독화 호흡기 세포융합 바이러스
WO2013026054A2 (fr) * 2011-08-18 2013-02-21 Axella Solutions, Llc Production de virus à arn infectieux dans une levure
WO2013031827A1 (fr) 2011-08-29 2013-03-07 国立大学法人徳島大学 Vaccin muqueux contre rsv
EP4190895A1 (fr) * 2013-02-08 2023-06-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Atténuation du virus respiratoire syncytial humain par désoptimisation de paire de codons à l'échelle du génome
PL2970981T3 (pl) * 2013-03-14 2021-07-05 Emory University Rekombinowany RSV z cichymi mutacjami, szczepionki i związane z nimi sposoby
US10429129B2 (en) 2013-10-16 2019-10-01 Merck Sharp & Dohme Corp. Method of microwave vacuum drying spherical-shaped pellets of biological materials
EP3057611A4 (fr) 2013-10-16 2017-04-12 Merck Sharp & Dohme Corp. Compositions de vaccins thermostables contre le virus respiratoire syncytial (rsv)
US10947512B2 (en) * 2015-08-14 2021-03-16 Research Institute At Nationwide Children's Hospital Respiratory syncytial virus having altered NS1 protein function and related materials and methods
SG11201803581VA (en) 2015-10-29 2018-05-30 Univ Emory Chimeric RSV, Immunogenic Compositions, and Methods of Use
US10808012B2 (en) 2016-09-23 2020-10-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
KR20200096904A (ko) * 2017-09-15 2020-08-14 오하이오 스테이트 이노베이션 파운데이션 호흡기 세포융합 바이러스(rsv) 감염의 예방을 위한 백신 및 백신의 제조 및 사용 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2250883A1 (fr) 1996-04-04 1997-10-16 The Regents Of The University Of Michigan Virus respiratoire syncytial attenue
BR9909076A (pt) 1998-03-26 2000-12-05 American Cyanamid Co Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b
KR100905450B1 (ko) 1999-07-09 2009-07-02 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 약독화된 인간-소 키메릭 호흡기 신시티움 바이러스백신의 제조 방법
WO2004028478A2 (fr) 2002-09-27 2004-04-08 Medimmune Vaccines, Inc. Mutations fonctionnelles du virus respiratoire syncytial
WO2004087062A2 (fr) * 2003-03-28 2004-10-14 Medimmune Vaccines, Inc. Compositions contenant un virus syncytial respiratoire de la souche 9320 du sous-groupe b, et procedes associes
WO2008096811A1 (fr) * 2007-02-07 2008-08-14 Dnavec Corporation Virus à arn à brin négatif atténué
KR20110063863A (ko) * 2008-11-05 2011-06-14 머크 샤프 앤드 돔 코포레이션 생 약독화 호흡기 세포융합 바이러스

Also Published As

Publication number Publication date
BRPI0921424A2 (pt) 2016-01-05
US20110212130A1 (en) 2011-09-01
EP2346990B1 (fr) 2016-01-06
ECSP11011033A (es) 2011-12-30
CO6362047A2 (es) 2012-01-20
US9011876B2 (en) 2015-04-21
TN2011000182A1 (en) 2012-12-17
WO2010053883A1 (fr) 2010-05-14
JP2011250798A (ja) 2011-12-15
RU2011122615A (ru) 2012-12-20
AU2009311287A1 (en) 2010-05-14
JP5743794B2 (ja) 2015-07-01
CL2011000999A1 (es) 2012-07-20
CN102272295A (zh) 2011-12-07
ZA201103259B (en) 2012-01-25
KR20110063863A (ko) 2011-06-14
JP2012507302A (ja) 2012-03-29
JP5016731B2 (ja) 2012-09-05
AU2009311287B2 (en) 2013-02-07
PE20110394A1 (es) 2011-06-22
AU2009311287C1 (en) 2015-02-19
MX2011004719A (es) 2011-05-31
CA2742086A1 (fr) 2010-05-14
EP2346990A1 (fr) 2011-07-27
IL212437A0 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
MA32878B1 (fr) Virus syncytial respiratoire vivant attenue
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
EA201070794A1 (ru) Рекомбинантные антигены rsv
CL2013002379A1 (es) Virus del sindrome reproductor y respiratorio porcino (prrsv); procedimiento para la preparacion del prrsv atenuado vivo; vacuna que lo comprende y su procedimiento de preparacion; y procedimiento para inmunizar cerdos contra el sindrome reproductor y respiratorio porcino.
EA201070066A1 (ru) Вакцины против гриппа с низким содержанием добавок
UA99659C2 (uk) Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
MX2009006178A (es) Vacuna contra salmonela.
MA31428B1 (fr) Vaccin
MX2009008928A (es) Composiciones que comprenden conjugados de polisacaridos y su uso como vacunas.
BRPI0516951A2 (pt) isolados da sÍndrome respiratària e reprodutora suÍna e mÉtodos de uso
WO2007047938A3 (fr) Matériaux et méthodes pour le contrôle d'une maladie respiratoire chez des canidés
WO2012021730A3 (fr) Vaccin contre le virus syncytial respiratoire (vsr)
ATE491720T1 (de) Impfstoff gegen pasteurella multocida
CY1113824T1 (el) Ενδορινικες συνθεσεις
CR11307A (es) Vacunas
WO2008010099A3 (fr) Procédé de production d'une souris multichimérique et applications à l'étude de l'immunopathogenèse de pathologies spécifiques de tissus humains
CL2007002710A1 (es) Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
WO2010101750A3 (fr) Salmonella enterica serovar paratyphi a atténuée et ses utilisations
WO2007010399A3 (fr) Proteine s trimerique purifiee comme vaccin contres des infections virales a syndrome respiratoire aigu severe
AR065765A1 (es) Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias
WO2007123906A3 (fr) Antigènes recombinés pour le diagnostic et la prévention du typhus murin
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа
ATE535253T1 (de) Impfstoff gegen mycoplasma prrsv
WO2016012406A3 (fr) Souche atténuée du vsrrp et son utilisation potentielle dans des préparations d'immunisation
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella